Abstract
Polygalacturonase-inhibiting proteins (PGIPs) are extracellular plant proteins bound to the plant cell wall containing leucine-rich repeats (LRR). They play an important role in plant defence being able to inhibit fungal endopolygalacturonases (EPGs), the first enzymes secreted by phytopathogenic fungi during plant infection. In the present work, a novel PGIP (LsPGIP) has been isolated from Lathyrus sativus seeds. LsPGIP exhibited an inhibitory activity towards EPGs from Aspergillus niger and Rhizopus spp. A pI value of 8.3 and a molecular mass of 40 kDa were determined for the purified inhibitor. Furthermore, N-terminal sequence up to residue 20 revealed that LsPGIP exhibit a high percentage of identity with PGIP from Actinidia deliciosa. A secondary structure similar to those of other polygalacturonase inhibitors was also inferred form circular dichroism data.
Keywords: Polygalacturonase-inhibiting protein, Edman degradation, Lathyrus sativus, protein purification, pathogens, β-1, 3-glucanases , protease inhibitors, glycoproteins, extracellular space, oligogalacturonides
Protein & Peptide Letters
Title:A Novel Polygalacturonase-Inhibiting Protein (PGIP) from Lathyrus sativus L. Seeds
Volume: 19 Issue: 8
Author(s): Rachele Tamburino, Angela Chambery, Augusto Parente and Antimo Di Maro
Affiliation:
Keywords: Polygalacturonase-inhibiting protein, Edman degradation, Lathyrus sativus, protein purification, pathogens, β-1, 3-glucanases , protease inhibitors, glycoproteins, extracellular space, oligogalacturonides
Abstract: Polygalacturonase-inhibiting proteins (PGIPs) are extracellular plant proteins bound to the plant cell wall containing leucine-rich repeats (LRR). They play an important role in plant defence being able to inhibit fungal endopolygalacturonases (EPGs), the first enzymes secreted by phytopathogenic fungi during plant infection. In the present work, a novel PGIP (LsPGIP) has been isolated from Lathyrus sativus seeds. LsPGIP exhibited an inhibitory activity towards EPGs from Aspergillus niger and Rhizopus spp. A pI value of 8.3 and a molecular mass of 40 kDa were determined for the purified inhibitor. Furthermore, N-terminal sequence up to residue 20 revealed that LsPGIP exhibit a high percentage of identity with PGIP from Actinidia deliciosa. A secondary structure similar to those of other polygalacturonase inhibitors was also inferred form circular dichroism data.
Export Options
About this article
Cite this article as:
Tamburino Rachele, Chambery Angela, Parente Augusto and Di Maro Antimo, A Novel Polygalacturonase-Inhibiting Protein (PGIP) from Lathyrus sativus L. Seeds, Protein & Peptide Letters 2012; 19 (8) . https://dx.doi.org/10.2174/092986612801619561
DOI https://dx.doi.org/10.2174/092986612801619561 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Human Obesity Epidemic - A Physiological Perspective
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Meet Our Associate Editor
Current Drug Metabolism Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry Clinical and Molecular Perspectives of Monogenic Hypertension
Current Hypertension Reviews Role of Islet-, Gut-, and Adipocyte-Derived Hormones in the Central Control of Food Intake and Body Weight: Implications for an Integrated Neurohormonal Approach to Obesity Pharmacotherapy
Current Diabetes Reviews Editorial [Hot Topic:Nicotinamide Adenine Dinucleotide Biology and Disease(Executive Editor: W. Todd Penberthy)]
Current Pharmaceutical Design Imidazoline Binding Sites in the Endocrine Pancreas: Can They Fulfil Their Potential as Targets for the Development of New Insulin Secretagogues?
Current Pharmaceutical Design Bio-Antioxidants – A Chemical Base of Their Antioxidant Activity and Beneficial Effect on Human Health
Current Medicinal Chemistry Biofilms: An Extra Hurdle for Effective Antimicrobial Therapy
Current Pharmaceutical Design Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options
Recent Patents on Anti-Cancer Drug Discovery Retinoids as Therapeutic Agents: Today and Tomorrow
Mini-Reviews in Medicinal Chemistry Human Apolipoprotein C-III – A New Intrahepatic Protein Factor Promoting Assembly and Secretion of Very Low Density Lipoproteins
Cardiovascular & Hematological Disorders-Drug Targets New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Immunotherapy for Malignant Melanoma Robert
Current Stem Cell Research & Therapy mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways
Current Neurovascular Research Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Synthesis, Structural Characterization and Docking Studies of Sulfamoyl- Phenyl Acid Esters as Dipeptidyl Peptidase-IV Inhibitors
Current Computer-Aided Drug Design New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Novel 4-Oxothienopyrimidinyl Propanoic Acid Derivatives as AMPActivated Protein Kinase (AMPK) Activators
Letters in Drug Design & Discovery Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews